Smith G P, Gibbs J
Fed Proc. 1984 Nov;43(14):2889-92.
In the past 10 years, numerous gut peptides have been tested for their satiating effect on food intake. Cholecystokinin (CCK), bombesin, pancreatic glucagon, and somatostatin have the best supporting evidence for such a specific behavioral effect. The satiety effect of CCK, somatostatin, and glucagon is abolished or markedly reduced by abdominal vagotomy, but the satiety effect of bombesin is not. The effect of vagotomy has been interpreted as the result of the loss of vagal afferent fibers that are necessary for carrying information about visceral effects of these peptides to the brain. This hypothesis is under active investigation. There are three reports that CCK decreases the size of a test meal in lean and obese humans. This suggests that CCK or the other peptides may be useful in treating human obesity and bulimia.
在过去十年中，众多肠道肽已被测试其对食物摄入的饱腹感作用。胆囊收缩素（CCK）、蛙皮素、胰高血糖素和生长抑素在这种特定行为效应方面有最有力的支持证据。CCK、生长抑素和胰高血糖素的饱腹感效应通过腹部迷走神经切断术被消除或显著降低，但蛙皮素的饱腹感效应不受影响。迷走神经切断术的效应被解释为迷走神经传入纤维丧失的结果，这些纤维对于将这些肽的内脏效应信息传递到大脑是必需的。这一假设正在积极研究中。有三份报告表明CCK可减小瘦人和肥胖人群的测试餐食量。这表明CCK或其他肽可能有助于治疗人类肥胖症和贪食症。
